A Study of TAS-120 in Patients With Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

407

Participants

Timeline

Start Date

July 21, 2014

Primary Completion Date

October 1, 2020

Study Completion Date

October 22, 2024

Conditions
CholangiocarcinomaUrothelial CancerAdvanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR TumorsPrimary CNS TumorsBreast CancerGastric Cancer
Interventions
DRUG

Futibatinib

oral once daily dosing, 21-day cycle

Trial Locations (58)

704

Cheng Kung University Hospital, Tainan City

10048

National Taiwan University Hospital, Taipei

14263

Roswell Park Cancer Institute, Buffalo

15232

University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh

19104

Hospital of the University of Pennsylvania, Philadelphia

19107

Sidney Kimmel Cancer Center at Jefferson, Philadelphia

20133

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan

22903

University of Virginia Cancer Center, Charlottesville

28034

University Hospital Ramón y Cajal, Madrid

29303

Spartanburg Medical Center, Spartanburg

29605

Greenville Health System ITOR,Clinical Research Unit, Greenville

30265

Cancer Treatment Centers of America, Newnan

33076

Institut Bergonie, Bordeaux

35042

Rennes, Centre Eugène Marquis, Rennes

35128

"UOC Oncologia Medica 1 IV - Istituto Oncologico Veneto - IRCCS", Padua

45147

University Hospital Essen, West German Cancer Center, Department of Medical Oncology, Essen

48201

Wayne State Universtity (Karmanos Cancer Institute), Detroit

53226

Medical College of Wisconsin, Milwaukee

53792

University of Wisconsin Clinical Science Center, Madison

55905

Mayo Clinic (MN), Rochester

60099

Cancer Treatment Centers of America Zion, IL, Zion

66205

The University of Kansas Cancer Center, Fairway

69373

Centre Léon Bérard Bât, Lyon

69677

Hospices Civils de Lyon, Bron

75013

Pitié-Salpêtrière Hospital, Paris

75230

Mary Crowley Cancer Research - Medical City, Dallas

77030

The University of Texas MD Anderson Cancer Center, Houston

84112

University of Utah, Huntsman Cancer Hospital, Salt Lake City

85234

Banner MD Anderson Cancer Center, Gilbert

85259

Mayo Clinic (AZ), Scottsdale

85719

The University of Arizona Cancer Center - North Campus, Tucson

87106

New Mexico Cancer Care Alliancer, Albuquerque

91010

City of Hope National Medical Center, Duarte

94158

UCSF Helen Diller Family Comprehensive Cancer Center. Mission Bay, San Francisco

94805

Institute Goustave-Roussy-DITEP, Villejuif

98101

Virginia Mason Cancer Center, Seattle

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institution, Boston

Unknown

Royal Melbourne Hospital, Melbourne

The Chinese University of Hong Kong, Shatin

Centro Integral Oncológico Clara Campal - Hospital Universitario Madrid Sanchinarro, Madrid

M4N3M5

Sunnybrook Research Institue, Toronto

060-8648

Hokkaido University Hospital, Hokkaido

606-8507

Kyoto University Hospital, Department of Clinical Pharmacology and Therapeutics, Kyoto

980-8574

Tohoku University Hospital, Miyagi

541-8567

Osaka International Cancer Institute, Osaka

104-0045

National Cancer Center Hospital, Tokyo

07740

University Hospital Jenna, Jenna

03722

Yonsei University, Severance Hospital (Seoul), Seoul

05505

ASAN Medical Center (Seoul), Seoul

06351

Samsung Medical Center (Seoul), Seoul

110-744

Seoul National University Hospital, Seoul

08035

Val D'Hebron University Hospital, Barcelona

08036

Hospital Clinic i Provincial de Barcelona,, Barcelona

SE1 9RT

Guy's and St Thomas' NHS Foundation Trust, London

W1G 6AD

Sarah Cannon Research Institute, London

W1T 7HA

University College London Hospital, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

All Listed Sponsors
lead

Taiho Oncology, Inc.

INDUSTRY

NCT02052778 - A Study of TAS-120 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter